<ul data-eligibleForWebStory="true"><li>A groundbreaking study introduces urine-based tumor DNA analysis for personalized bladder cancer therapy.</li><li>The research utilizes utDNA to predict recurrence risk in high-risk NMIBC patients undergoing atezolizumab.</li><li>Positive utDNA after immunotherapy indicates higher recurrence risk, guiding treatment escalation decisions.</li><li>This innovative approach offers potential for tailored treatments and improved patient outcomes in bladder cancer.</li></ul>

Innovative Urine-Based Tumor DNA Test Promises Personalized Bladder Cancer Therapy

Discover more